1. Home
  2. BSEM vs CING Comparison

BSEM vs CING Comparison

Compare BSEM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioStem Technologies Inc. Common Stock

BSEM

BioStem Technologies Inc. Common Stock

HOLD

Current Price

$1.15

Market Cap

76.9M

Sector

Health Care

ML Signal

HOLD

CING

Cingulate Inc.

SELL

Current Price

$4.56

Market Cap

70.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BSEM
CING
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
70.2M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
BSEM
CING
Price
$1.15
$4.56
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $21.20
AVG Volume (30 Days)
★ 155.2K
113.1K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$87.68
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$3.16
52 Week High
$5.44
$11.89

Technical Indicators

Market Signals
Indicator
BSEM
CING
Relative Strength Index (RSI) 23.28 44.76
Support Level N/A $4.70
Resistance Level $4.65 $5.31
Average True Range (ATR) 0.24 0.31
MACD -0.01 0.03
Stochastic Oscillator 8.73 38.57

Price Performance

Historical Comparison
BSEM
CING

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: